Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 6Phase 3 5Phase 1 2

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 5Genitourinary 2Tumor-Agnostic 1

Conditions

Fallopian Tube Neoplasms 5Ovarian Neoplasms 4Carcinoma, Ovarian Epithelial 3Recurrence 1Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Genital Neoplasms, Male 1Adenocarcinoma, Clear Cell 1

Interventions

Paclitaxel 150Carboplatin 110Cisplatin 94Bevacizumab 42Topotecan 39Gemcitabine 38liposomal doxorubicin 34Radiotherapy 29Doxorubicin 27Brachytherapy 26Taxes 24pembrolizumab 20olaparib 20Drug Therapy 20Hyperthermic Intraperitoneal Chemotherapy 16Chemotherapy, Adjuvant 16human papillomavirus vaccine, L1 type 16, 18 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 14Docetaxel 13Neoadjuvant Therapy 12Platinum 10niraparib 9Radiation 91,2-diaminocyclohexaneplatinum II citrate 9Vaccines, Synthetic 8Surgical Procedures, Operative 8atezolizumab 7Specimen Handling 7Papillomavirus Vaccines 7Letrozole 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × rucaparib × Gynecologic × Clear all
NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT04227522 2024-11-15

MAMOC

North Eastern German Society of Gynaecological Oncology

Phase 3 Completed
42 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Adenocarcinoma, Clear Cell

NCT04676334 2024-05-07

CATCH-R

pharmaand GmbH

Phase 3 Completed
34 enrolled 9 charts
GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Genital Neoplasms, Male, Ovarian Neoplasms, Prostatic Neoplasms

NCT01968213 2023-06-09

ARIEL3

pharmaand GmbH

Phase 3 Completed
564 enrolled 18 charts 1 FDA
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02855944 2023-06-09

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

pharmaand GmbH

Phase 3 Completed
349 enrolled 29 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡